Paczek L, Lao M, Durlik M, Szmidt J, Rowinski W
Transplantation Institute, Medical University of Warsaw, Warsaw, Poland.
Transplant Proc. 2004 Mar;36(2 Suppl):173S-176S. doi: 10.1016/j.transproceed.2004.01.030.
This paper presents experience with cyclosporine A in kidney allograft recipients at the Transplantation Institute, the Medical University of Warsaw. Comparative studies on pharmacokinetics and bioavailability of CsA and Neoral as well as monitoring of the drug immunosuppressive activity are presented. The implementation of CsA to immunosuppressive therapy in renal allograft recipients have greatly improved the grafts and patients survival. CsA has been used in a great percentage of patients after renal allograft in Poland (72%) and seems to be in some patients the gold standard of immunosuppression.
本文介绍了华沙医科大学移植研究所对肾移植受者使用环孢素A的经验。文中还呈现了环孢素A（CsA）和新山地明（Neoral）的药代动力学及生物利用度的对比研究，以及对该药物免疫抑制活性的监测。在肾移植受者的免疫抑制治疗中使用CsA，极大地提高了移植物和患者的存活率。在波兰，很大比例的肾移植患者（72%）使用了CsA，而且在一些患者中，它似乎是免疫抑制的金标准。
